2018 EAU Male Hypogonadism Guidelines Scope Search Database: Embase <1974 to 2017 June 2>, OVID Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials <April 2017>, EBM Reviews - Cochrane Database of Systematic Reviews <2005 to May 31, 2017> Search Strategy: -------------------------------------------------------------------------------- 1 exp hypogonadism/ (27031) 2 (eugonadal or hypogonadism or hypogonadal or gonadal).tw,kw. (83468) 3 ((low or lower or reduction or absence) adj5 (testosterone* or (hormone and testes))).tw. (17714) 4 1 or 2 or 3 (107893) 5 limit 4 to yr="2011 -Current" (30615) 6 female/ not (exp male/ or (men or man or male*).tw.) (5254378) 7 female to male transgender/ or (male transgender* or transsexual or trans men).tw. (2856) 8 5 not (6 or 7) (26388) 9 randomized controlled trial.pt. (886547) 10 random:.mp. (3143566) 11 controlled clinical trial.pt. (183474) 12 clinical trial:.mp. or clinical trial.pt. (2862164) 13 double-blind:.mp. or blind:.tw. (942264) 14 (trial or groups or placebo).ab. (5434601) 15 (Systematic review or meta-analysis).tw,kw. (375335) 16 Meta analysis/ or "systematic review"/ (294690) 17 (Medline or Pubmed Embase or Cochrane or literature search or literature review).ab. (379762) 18 or/9-17 (8720691) 19 8 and 18 (6971) 20 ((exp animals/ or exp animal/ or exp nonhuman/ or exp animal experiment/ or animal model/ or animal tissue/ or non human/) not (humans/ or human/)) or ((rats or mice or mouse or cats or dogs or animal* or cell lines) not (human* or men or women)).ti. (11027679) 21 ((child/ or Pediatrics/ or Adolescent/ or Infant/ or adolescence/ or newborn/) not adult/) or ((child or children or pediatric* or paediatric* or peadiatric* or infant* or new born or adolescent or preschool or pre-school or youth* or student*) not (aged or adult* or senior or men or women)).ti. (4364675) 22 conference abstract.pt. or Congresses as Topic/ (2673462) 23 case report/ or case reports/ or (case report or case series).ti. (4169069) 24 note/ or editorial/ or letter/ or Comment/ or news/ (3890492) 25 or/20-24 (23755591) 26 19 not 25 (3844) 27 limit 26 to english language [Limit not valid in CDSR; records were retained] (3654) 28 prostate cancer.ti. (152880) 29 27 not 28 (3424) 30 remove duplicates from 29 (2278) 31 limit 30 to ed=20160526-20170602 use ppez [Limit not valid in Embase,CCTR,CDSR; records were retained] (39) 32 limit 30 to dd=20160526-20170602 use oemezd [Limit not valid in Ovid MEDLINE(R),Ovid MEDLINE(R) Daily Update,Ovid MEDLINE(R) In-Process,Ovid MEDLINE(R) Publisher,CCTR,CDSR; records were retained] (271) 33 2017*.dc. or 2017*.ep. (1329560) 34 30 and 33 (214) 35 limit 30 to yr="2016 -Current" use coch (15) 36 limit 30 to yr="2016 -Current" use cctr (65) 37 31 or 32 or 34 or 35 or 36 (464) *************************** 1. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists De Sousa SMC, Chapman IM, Falhammar H, Torpy DJ EBM Reviews - Cochrane Central Register of Controlled Trials Endocrine. 55(2):618-624, 2017. [Journal: Article] AN: CN-01327741 NEW Dopamine agonists are the first line of therapy for prolactinomas, with high rates of biochemical control and tumour shrinkage. Toxicity is considered to be low and manageable by switching of agents and dose reduction. Dopamine agonist-induced impulse control disorders are well Page 2 described in the neurology setting, but further data are required regarding this toxicity in prolactinoma patients. We performed a multicenter retrospective cohort study of eight men with prolactinomas and associated central hypogonadism. The eight men had no prior history of psychiatric disease, but each developed disruptive hypersexuality whilst on dopamine agonist therapy at various doses. Cabergoline, bromocriptine and quinagolide were all implicated. Hypersexuality had manifold consequences, including relationship discord, financial loss, reduced work performance, and illicit activity. We hypothesise that this phenomenon is due to synergy between reward pathway stimulation by dopamine agonists, together with rapid restoration of the eugonadal state after prolonged hypogonadism. We refer here to this distinct drug toxicity as 'dopa-testotoxicosis'. Given the profound impact in these patients and their families, cessation of dopamine agonists should be considered in men who develop hypersexuality, and pituitary surgery may be required to facilitate this. Awareness of this distinct impulse control disorder should enable further research into the prevalence, natural history and management of dopa- testotoxicosis. The condition is likely under-reported due to the highly personal nature of the symptoms and we suggest a simple written questionnaire to screen for hypersexuality and other behavioural symptoms within the first six months of dopamine agonist treatment. Copyright (C) 2016, Springer Science+Business Media New York. Institution S.M.C. De Sousa, Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia. E- mail: [email protected] Publisher Humana Press Inc. (E-mail: [email protected]) 2. Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC) Feng Z, Wen H, Ju X, Bi R, Chen X, Yang W, Wu X EBM Reviews - Cochrane Central Register of Controlled Trials Journal of ovarian research. 10(1) (no pagination):2017. [Journal: Article] AN: CN-01327789 NEW Background: The aim of our study was to investigate the clinical features and expression levels of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian Page 3 cancer (LGSC). Methods: We retrospectively investigated the clinical features of 26 consecutive patients with LGSC who underwent primary staging or debulking surgery between April 2005 and June 2013 in our center; concomitant primary high-grade serous ovarian cancer (HGSC) patients were randomly selected at a 2:1 ratio for comparison. Tissue microarrays were constructed from the LGSC and HGSC specimens, and the expression levels of six hormone receptors in the hypothalamic pituitary-gonadal axis were analyzed by immunohistochemistry. Results: The median (range) age of patients with LGSC was 54 (27-77) years. According to the FIGO staging system, the cases were distributed as follows: stage I, 6 (23.1%); stage II, 0 (0%); stage III, 19 (73.1%); and stage IV, 1 (3.8%). The 2-year and 5-year overall survival rates for LGSC were 91.8% and 67.5%, respectively. The expression levels of the hormone receptors were as follows: ER, 80.8%; PR, 34.6%; AR, 53.8%; FSHR, 84.0%; LHR, 65.4%; and GnRHR, 100%. Hormone receptor-positive patients had a better prognosis compared with hormone receptor-negative patients, but the difference was not significant. Conclusions: Our study presented a higher overall survival rate and distinctive hormone receptor expression levels of LGSC patients compared with the HGSC cohort. Patients with positive hormone receptor expression tended to have a better prognosis than the corresponding hormone receptor negative patients. Copyright (C) 2017 The Author(s). Institution X. Wu, Department of Gynecological Oncology, Fudan University, Shanghai Cancer Center, 270 Dong-an Road, Shanghai 200032, China. E-mail: [email protected] Publisher BioMed Central Ltd. (E-mail: [email protected]) 3. Dopa-testotoxicosis: a novel drug toxicity of dopamine agonists in male prolactinoma patients De Sousa SMC, Chapman IM, Falhammar H, Torpy DJ EBM Reviews - Cochrane Central Register of Controlled Trials Clinical endocrinology. Conference: endocrine society of australia annual scientific meeting. 2016. Australia. Conference start: 20160821. Conference end: 20160824 Vol.86, pp.18, 2017. [Journal: Conference Abstract] AN: CN-01334018 NEW Background: Impulse control disorders (ICD) including gambling, hypersexuality, compulsive shopping and binge eating have recently been recognised as side effects of dopamine agonists Page 4 (DAs). The vast majority has been described in the treatment of Parkinson's disease and restless legs syndrome where pathological gambling is the predominant DA-associated ICD (1). Little is known about the nature of ICDs in the prolactinoma setting where endocrine factors, specifically testosterone fluctuations, may influence behaviour (2). Methods: We performed a multicenter retrospective cohort study of eight men who developed hypersexuality following initiation of DA therapy for prolactinomas. Results: The men had no prior history of psychiatric disease, but each developed disruptive hypersexuality with manifold consequences, including relationship discord, financial loss, reduced work performance, and illicit activity. Two men also developed pathological gambling. Cabergoline, bromocriptine and quinagolide were all implicated. The onset of hypersexuality ranged from days to years after DA commencement. Some men notably had normal pre-treatment testosterone levels, however these values were in the lower half of the reference range and rose into the upper half with DA initiation suggesting they had relative hypogonadism at baseline. Six men received no androgen replacement and increases in testosterone were solely attributable to DA therapy. Prolactin and testosterone consistently improved to be close or within the reference range by the time of symptom onset. Symptoms were reversible with DA cessation. Conclusions: